Syapse to utilize NCCN Biomarkers Compendium for clinical care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Comprehensive Cancer Network and Syapse announced an agreement w to expand the use of best practices in precision medicine.

Syapse delivers solutions for scaling enterprise precision oncology programs. The data contained in the NCCN Biomarkers Compendium will strengthen Syapse’s decision support and workflow tools, increasing access to more personalized care.

The NCCN Biomarkers Compendium is part of NCCN’s Library of Compendia, which also includes databases for Drugs & Biologics (NCCN Compendium), as well as the NCCN Radiation Therapy Compendium, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC).

The NCCN-supported data will begin appearing on the Syapse platform in late 2018. Syapse is committed to updating that content weekly to keep pace with the NCCN Guidelines.

Table of Contents

YOU MAY BE INTERESTED IN

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men. 
Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login